Parathyroid Scintigraphy
Parathyroid Scintigraphy
Hyperparathyroidism
Objectives
- Anatomy and Physiology
- Pathophysiology
- Protocol
- Radiopharmaceutical, dose
- Imaging parameters/acquisition
- Indications
- Contraindications
- Precautions
- Review of images
Anatomy
- Location:
- Situated on the posterolateral surface of the upper and lower thyroid lobes.
- Glands:
- Typically four parathyroid glands.
- Normal size resembles that of rice but can be as large as a pea.
- Characteristic mustard yellow color.
Ectopic Sites
- Ectopic parathyroid glands can be found in:
- Thymus
- Neck
- Chest
- Embedded within the thyroid gland.
- Surrounded by a sheath related to the carotid artery and jugular vein.
Parathyroid Hormone (PTH) Function
- Calcium Regulation:
- Plays a vital role in maintaining calcium homeostasis, specifically in the range of 8-10 mg/dL.
- Vitamin D Metabolism:
- Negative Feedback Loop:
- When blood calcium levels decrease, PTH is released.
- PTH acts on:
- Kidneys: Retains calcium and activates Vitamin D.
- Intestines: Increases absorption of calcium.
- Skeletal System: Stimulates osteoclasts that resorb bone tissue.
Symptoms and Effects of Hyperparathyroidism
- Digestive System:
- Loss of appetite
- Nausea and vomiting
- Constipation
- Nervous System:
- Fatigue
- Depression
- Confusion
- Musculoskeletal System:
- Muscle weakness
- Aches and pains in bones and joints
- Urinary System:
- Kidney stones
- Increased thirst
- Increased urination
Types of Hyperparathyroidism
- Primary Hyperparathyroidism:
- Caused by parathyroid gland pathology.
- Characterized by elevated PTH (normal range: 10-65 pg/mL) and normal or elevated calcium levels.
- Causes may include solitary or multiple adenomas or hyperplasia.
- Secondary Hyperparathyroidism:
- Occurs due to conditions causing hypocalcemia.
- Elevated PTH with normal or low serum calcium.
- Often related to chronic renal disease, known as renal hyperparathyroidism (HPT).
- Tertiary Hyperparathyroidism:
- Develops during the course of secondary hyperparathyroidism.
- Characterized by elevated calcium and PTH due to untreated secondary hyperparathyroidism and autonomous PTH adenoma.
Clinical Presentation of Primary Hyperparathyroidism (PHPT)
- Most common presentation is asymptomatic hypercalcemia.
- Other observations include:
- Elevated or high-normal intact PTH concentration.
- Elevated or normal serum calcium levels.
- Potentially leading to bone pain, muscle weakness, osteoporosis, or fractures.
- Treatment: Surgical resection.
Secondary Hyperparathyroidism
- Causes include:
- Renal insufficiency
- Vitamin D deficiency
- Malabsorption
- Osteomalacia and rickets.
- Associated symptoms:
- Bone pain
- Muscular weakness
- Osteoporosis/osteopenia
- Risk of fractures.
- Treatment: Reducing phosphate uptake, calcium-containing preparations that bind phosphates, and Calcitriol supplementation. Surgery may also be an option.
Tertiary Hyperparathyroidism
- Characterized by:
- Hypercalcemia arising during secondary hyperparathyroidism.
- Autonomous PTH adenoma leading to continual PTH secretion from hyperplastic glands.
- Accompanied by elevated PTH and calcium levels.
Comparative Overview of Hyperparathyroidism Types
| Type | Pathology | Serum PTH Level | Serum Calcium Level | Management |
|---|---|---|---|---|
| Primary | Hyperfunctioning due to adenoma, hyperplasia, or carcinoma | High | High/Normal | Surgery; Cinacalcet if surgery is not feasible |
| Secondary | Physiological stimulation due to hypocalcemia | High | Low/Normal | Treatment of underlying cause; Cinacalcet |
| Tertiary | Following long-term stimulation leading to hyperplasia | Very High | High/Normal | Cinacalcet; Surgery if unresponsive |
Quiz Questions
- Question 1: When blood calcium levels are low, PTH stimulates:
- A. Urinary excretion of calcium by the kidneys.
- B. A reduction in calcium absorption from the intestines.
- C. The activity of osteoblasts.
- D. The activity of osteoclasts.
- Question 2: Which of the following can result from hyperparathyroidism?
- A. Increased bone deposition.
- B. Fractures.
- C. Convulsions.
- D. All of the above.
Clinical Refreshers
Parathyroid Scintigraphy
- Focus on the most commonly performed clinical practices.
Indications for Parathyroid Scintigraphy
- Detection and localization of:
- Primary and secondary hyperparathyroidism.
- Identification of single or multiple adenomas or glandular hyperplasia in patients.
- Localization for surgical intervention.
- Identifying parathyroid tissue post-surgery for persistent or recurrent hyperparathyroidism (elevated PTH and calcium levels).
Contraindications
- Patients unable to remain still (e.g., agitated, claustrophobic).
- Pregnancy or lactation.
Patient History Questions
- Previous lab results for calcium (Ca2+) and PTH levels.
- Possible Vitamin D levels.
- Results of DMI test.
- History of thyroid disease, especially nodular thyroid disease.
- Recent iodine-containing contrast or thyroid hormone treatments.
- If thyroid imaging and subtraction studies are involved.
- Previous thyroid surgeries or treatments (e.g., Thyroidectomy or RAI therapy).
- Symptoms such as muscle fatigue, osteoporosis, kidney stones, and neck tenderness/swellings.
Dual Phase Method
- Overview: Evaluates the distribution of the radiopharmaceutical over several hours, divided into two phases:
- Thyroid phase: Initial uptake observed in thyroid and surrounding tissues including salivary glands, heart, gallbladder, and gut, but with possible indistinctiveness in parathyroid.
- Delayed phase: Focused imaging to observe specific parathyroid uptake.
Radiopharmaceuticals Used
- Commonly used agents:
- Tc99m sestamibi or Tc99m tetrofosmin:
- Standard dose: 740 MBq (20 mCi) IV.
- Range: 740–1110 MBq (20–30 mCi).
- Mechanism of Action: Passive transport correlating with blood flow to thyroid and parathyroid tissue, remaining longer in adenomatous and hyperplastic tissue.
Single Isotope Imaging Protocol (Tc99m sestamibi)
- Early Phase (Thyroid Phase):
- Inject Tc99m sestamibi and wait 10-30 min.
- Patient in waters position.
- Scanning neck and chest through SPECT or SPECT/CT imaging.
Imaging Parameters for SPECT
- Imaging duration: approximately 25 minutes.
- Configuration: circular or non-circular, with 360° rotation.
- Matrix dimensions: 128 x 128, with 120 projections, and stop duration of 15-25 sec per capture.
Delayed Phase Imaging
- At 1.5-2.5 hours post-injection: perform repeat imaging of the neck and chest, using planar, SPECT, or SPECT/CT as required.
Other Radiopharmaceuticals for Dual Isotope Imaging
- Tc99m pertechnetate: used with a dosage of 74 MBq (2 mCi) IV, with a range of 74–370 MBq (2–10 mCi).
- I123 NaI: administered orally at 7.5 MBq (200 µCi), with a range from 7.5–22 MBq (200–600 µCi).
Dual-isotope Protocol Options
First Option:
- Administer Tc99m pertechnetate, wait 30 minutes, and capture anterior images.
- Inject Tc99m sestamibi, wait 10 minutes, repeat imaging.
Second Option:
- Administer Tc99m sestamibi first, wait 10 minutes, then inject Tc99m pertechnetate, waiting 30 minutes before imaging.
Dual-Isotope Protocol (123I/99mTc-sestamibi)
- First, administer 123I, wait 4 hours, then capture anterior neck and chest images.
- Administer Tc99m sestamibi, wait 10 minutes, and repeat imaging.
Image Processing
- Scale planar images to accurately visualize areas of normal anatomy.
- Label images with projection information and any dose or technologist identification.
- Process SPECT or SPECT/CT images according to manufacturer recommendations.
- Normalization and Subtraction:
- For dual-isotope protocols, normalize images to total thyroid counts and then apply computer subtraction method to obtain clearer images.
Summary
- Various imaging techniques are brought together for parathyroid scintigraphy, focusing on the detection and management of hyperparathyroidism issues through a detailed, phased approach using specific radiopharmaceuticals and imaging protocols.